{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:28:31Z","timestamp":1793899711543,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14127-y","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:16:21Z","timestamp":1788758181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9570-6403","authenticated-orcid":false,"given":"Fady","family":"Tawfik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Sienkaniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humzah","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Guidry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"3","key":"14127_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jama.2025.19400","volume":"335","author":"ML Mauermann","year":"2026","unstructured":"Mauermann ML, Staff NP (2026) Peripheral neuropathy: a review. JAMA 335(3):255\u2013266. https:\/\/doi.org\/10.1001\/jama.2025.19400","journal-title":"JAMA"},{"key":"14127_CR2","unstructured":"Bodman MA, Dreyer MA, Varacallo MA. (2026) Diabetic Peripheral Neuropathy. [Updated 2024 Feb 25]. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK442009\/"},{"issue":"2","key":"14127_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/mus.20785","volume":"36","author":"DW Zochodne","year":"2007","unstructured":"Zochodne DW (2007) Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 36(2):144\u2013166. https:\/\/doi.org\/10.1002\/mus.20785","journal-title":"Muscle Nerve"},{"key":"14127_CR4","unstructured":"Collins AC, Bergman R. (2026) Charcot Neuropathic Osteoarthropathy. [Updated 2026 Jan 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470164\/"},{"issue":"Pt 1","key":"14127_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/brain\/awu307","volume":"138","author":"CH Gibbons","year":"2015","unstructured":"Gibbons CH, Freeman R (2015) Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 138(Pt 1):43\u201352. https:\/\/doi.org\/10.1093\/brain\/awu307","journal-title":"Brain"},{"issue":"9","key":"14127_CR6","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2337\/db10-1462","volume":"60","author":"T Himeno","year":"2011","unstructured":"Himeno T, Kamiya H, Naruse K et al (2011) Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 60(9):2397\u20132406. https:\/\/doi.org\/10.2337\/db10-1462","journal-title":"Diabetes"},{"key":"14127_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1268619","volume":"14","author":"C Liu","year":"2024","unstructured":"Liu C, Wu T, Ren N (2024) Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy. Front Endocrinol (Lausanne) 14:1268619. https:\/\/doi.org\/10.3389\/fendo.2023.1268619","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"14127_CR8","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3892\/ijmm.2018.3509","volume":"41","author":"J Ma","year":"2018","unstructured":"Ma J, Shi M, Zhang X et al (2018) GLP\u20111R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK\/NF\u2011\u03baB signaling pathways in streptozotocin\u2011induced diabetic rats. Int J Mol Med 41(5):2977\u20132985. https:\/\/doi.org\/10.3892\/ijmm.2018.3509","journal-title":"Int J Mol Med"},{"issue":"3","key":"14127_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","volume":"67","author":"R Dhanapalaratnam","year":"2024","unstructured":"Dhanapalaratnam R, Issar T, Lee ATK et al (2024) Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia 67(3):561\u2013566. https:\/\/doi.org\/10.1007\/s00125-023-06072-6","journal-title":"Diabetologia"},{"issue":"2","key":"14127_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16242","volume":"169","author":"S Fan","year":"2025","unstructured":"Fan S, Qiu Y, Liu J et al (2025) Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: a meta-analysis. J Neurochem 169(2):e16242. https:\/\/doi.org\/10.1111\/jnc.16242","journal-title":"J Neurochem"},{"issue":"Supplement_1","key":"14127_CR11","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.2337\/dc26-S012","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2026. Diabetes Care 49(Supplement_1):S261\u2013S276. https:\/\/doi.org\/10.2337\/dc26-S012","journal-title":"Diabetes Care"},{"issue":"10","key":"14127_CR12","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","volume":"66","author":"J Goldney","year":"2023","unstructured":"Goldney J, Sargeant JA, Davies MJ (2023) Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia 66(10):1832\u20131845. https:\/\/doi.org\/10.1007\/s00125-023-05988-3","journal-title":"Diabetologia"},{"issue":"10","key":"14127_CR13","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.2337\/dc25-0292","volume":"48","author":"AT Hong","year":"2025","unstructured":"Hong AT, Luu IY, Lin F et al (2025) Differential effect of GLP-1 receptor agonists and SGLT2 inhibitors on lower-extremity amputation outcomes in type 2 diabetes: a nationwide retrospective cohort study. Diabetes Care 48(10):1728\u20131736. https:\/\/doi.org\/10.2337\/dc25-0292","journal-title":"Diabetes Care"},{"issue":"5","key":"14127_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2337\/dc25-2120","volume":"49","author":"JB Bonnet","year":"2026","unstructured":"Bonnet JB, Huguet H, Avignon A, Duflos C, Sultan A (2026) GLP-1 receptor agonists are associated with reduced mortality following diabetic foot ulcers: a nationwide observational study. Diabetes Care 49(5):730\u2013739. https:\/\/doi.org\/10.2337\/dc25-2120","journal-title":"Diabetes Care"},{"key":"14127_CR15","unstructured":"TriNetX. TriNetX Research Network. https:\/\/trinetx.com. Accessed May 24, 2026."},{"issue":"12","key":"14127_CR16","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1016\/j.jid.2025.08.045","volume":"145","author":"J Ghebrehiwet-Kuflom","year":"2025","unstructured":"Ghebrehiwet-Kuflom J, Mehta A, Lim P, Dahle S, Isseroff RR (2025) GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic cutaneous wound healing. J Invest Dermatol 145(12):2981\u20132988. https:\/\/doi.org\/10.1016\/j.jid.2025.08.045","journal-title":"J Invest Dermatol"},{"key":"14127_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114050","volume":"147","author":"H Yue","year":"2025","unstructured":"Yue H, Zhang X, Zhao Z, Gong S, Shao S (2025) Pro-healing impact of liraglutide on skin wounds in normoglycemic mice. Int Immunopharmacol 147:114050. https:\/\/doi.org\/10.1016\/j.intimp.2025.114050","journal-title":"Int Immunopharmacol"},{"key":"14127_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","volume":"146","author":"K Nagae","year":"2018","unstructured":"Nagae K, Uchi H, Morino-Koga S, Tanaka Y, Oda M, Furue M (2018) Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes. Diabetes Res Clin Pract 146:155\u2013161. https:\/\/doi.org\/10.1016\/j.diabres.2018.10.013","journal-title":"Diabetes Res Clin Pract"},{"key":"14127_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jss.2016.09.024","volume":"208","author":"JN Roan","year":"2017","unstructured":"Roan JN, Cheng HN, Young CC et al (2017) Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res 208:93\u2013103. https:\/\/doi.org\/10.1016\/j.jss.2016.09.024","journal-title":"J Surg Res"},{"key":"14127_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2026.01.012","author":"RG McCoy","year":"2026","unstructured":"McCoy RG, Swarna KS, Polley EC et al (2026) Lower extremity complications in adults with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas: an emulated target trial. Endocr Pract. https:\/\/doi.org\/10.1016\/j.eprac.2026.01.012","journal-title":"Endocr Pract"},{"issue":"3","key":"14127_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7326\/ANNALS-25-01262","volume":"179","author":"FPB Kristensen","year":"2026","unstructured":"Kristensen FPB, Christensen DH, Callaghan BC et al (2026) Effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists on diabetic foot disease\u202f: an emulated target trial. Ann Intern Med 179(3):340\u2013352. https:\/\/doi.org\/10.7326\/ANNALS-25-01262","journal-title":"Ann Intern Med"},{"issue":"9","key":"14127_CR22","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1111\/dom.15721","volume":"26","author":"NCC Werkman","year":"2024","unstructured":"Werkman NCC, Driessen JHM, Klungel OH et al (2024) Incretin-based therapy and the risk of diabetic foot ulcers and related events. Diabetes Obes Metab 26(9):3764\u20133780. https:\/\/doi.org\/10.1111\/dom.15721","journal-title":"Diabetes Obes Metab"},{"key":"14127_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mus.27048","volume":"63","author":"D Kaur","year":"2021","unstructured":"Kaur D, Tiwana H, Stino A, Sandroni P (2021) Autonomic neuropathies. Muscle Nerve 63:10\u201321. https:\/\/doi.org\/10.1002\/mus.27048","journal-title":"Muscle Nerve"},{"issue":"3","key":"14127_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/BF00418349","volume":"39","author":"S Tesfaye","year":"1996","unstructured":"Tesfaye S, Malik R, Harris N et al (1996) Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 39(3):329\u2013335. https:\/\/doi.org\/10.1007\/BF00418349","journal-title":"Diabetologia"},{"issue":"7","key":"14127_CR25","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2337\/dc21-2508","volume":"45","author":"W Jeffcoate","year":"2022","unstructured":"Jeffcoate W, Game F (2022) The Charcot foot reflects a response to injury that is critically distorted by preexisting nerve damage: an imperfect storm. Diabetes Care 45(7):1691\u20131697. https:\/\/doi.org\/10.2337\/dc21-2508","journal-title":"Diabetes Care"},{"issue":"5","key":"14127_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233168","volume":"15","author":"D Dardari","year":"2020","unstructured":"Dardari D, Van GH, M\u2019Bemba J et al (2020) Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot\u2019s acute neuroarthropathy. PLoS One 15(5):e0233168. https:\/\/doi.org\/10.1371\/journal.pone.0233168","journal-title":"PLoS One"},{"issue":"2","key":"14127_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.tem.2022.12.003","volume":"34","author":"D Dardari","year":"2023","unstructured":"Dardari D (2023) Trends in the pathophysiology of Charcot neuroarthropathy. Trends Endocrinol Metab 34(2):61\u201362. https:\/\/doi.org\/10.1016\/j.tem.2022.12.003","journal-title":"Trends Endocrinol Metab"},{"key":"14127_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3646","author":"DK Wukich","year":"2023","unstructured":"Wukich DK, Schaper NC, Gooday C et al (2023) Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes Metab Res Rev. https:\/\/doi.org\/10.1002\/dmrr.3646","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"14127_CR29","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.OA.25.00261","volume":"11","author":"O Embaby","year":"2026","unstructured":"Embaby O, Asmadi AB, Asmadi AB, Elalfy M (2026) Decoding chronic Charcot arthropathy: molecular mechanisms, predictive biomarkers, and emerging therapies. JB JS Open Access 11(1):e25.00261. https:\/\/doi.org\/10.2106\/JBJS.OA.25.00261","journal-title":"JB JS Open Access"},{"issue":"8","key":"14127_CR30","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.2337\/db10-1220","volume":"60","author":"A Ndip","year":"2011","unstructured":"Ndip A, Williams A, Jude EB et al (2011) The RANKL\/RANK\/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 60(8):2187\u20132196. https:\/\/doi.org\/10.2337\/db10-1220","journal-title":"Diabetes"},{"issue":"9","key":"14127_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13553","volume":"74","author":"R Herrera Comoglio","year":"2020","unstructured":"Herrera Comoglio R, Vidal Guitart X (2020) Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): a systematic review and meta-analysis of observational cohort studies. Int J Clin Pract 74(9):e13553. https:\/\/doi.org\/10.1111\/ijcp.13553","journal-title":"Int J Clin Pract"},{"issue":"10","key":"14127_CR32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7(10):776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"14127_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/CLEP.S124054","volume":"9","author":"MZ Ankarfeldt","year":"2017","unstructured":"Ankarfeldt MZ, Thorsted BL, Groenwold RH, Adalsteinsson E, Ali MS, Klungel OH (2017) Assessment of channeling bias among initiators of glucose-lowering drugs: a UK cohort study. Clin Epidemiol 9:19\u201330. https:\/\/doi.org\/10.2147\/CLEP.S124054","journal-title":"Clin Epidemiol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14127-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:05:46Z","timestamp":1793898346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14127-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14127"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14127-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was determined to be exempt from review by the Howard University Hospitals Institutional Review Board (IRB), as it involved the retrospective analysis of de-identified patient data obtained from the TriNetX Global Collaborative Network. No identifiable private information was collected or recorded, and there was no direct interaction with patients. As such, the research qualifies for exemption under 45 CFR 46.104(d)(4). Informed consent was not required. All research activities were carried out in accordance with the guidelines and regulations of the Howard University Hospitals Institutional Review Board and in compliance with the ethical principles outlined in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical Publication and Informed Consent Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"569"}}